Market: NASD |
Currency: USD
Address: 590 Madison Avenue
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; and HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Show more
📈 Hoth Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$5.00
-
Upside/Downside from Analyst Target:
331.03%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
2022 |
- |
$0.040000 |
- |
2022-10-26 |
- |
Stock split |
Total Amount for 2022: $0.040000 |
📅 Earnings & EPS History for Hoth Therapeutics, Inc.
Date | Reported EPS |
---|
2025-08-12 | -0.17 |
2025-05-12 | -0.27 |
2025-03-28 | -0.32 |
2024-11-12 | -0.31 |
2024-08-09 | -0.24 |
2024-05-14 | -0.46 |
2024-03-28 | -0.31 |
2023-11-13 | -0.6 |
2023-08-11 | -0.57 |
2023-05-15 | -0.88 |
2023-03-31 | -2.72 |
2022-11-10 | -2.05 |
2022-08-12 | -2.25 |
2022-05-12 | -2.75 |
2022-03-30 | -3.5 |
2021-11-10 | -3.5 |
2021-08-11 | -3.5 |
2021-05-13 | -6 |
2021-03-16 | -1 |
2020-11-10 | -4 |
2020-08-13 | -5 |
2020-05-13 | -4.5 |
2020-03-01 | -10.25 |
2019-11-12 | -4.25 |
2019-08-14 | -3.25 |
📰 Related News & Research
No related articles found for "hoth therapeutics".